Omnicell (OMCL) Projected to Announce Quarterly Earnings on Thursday

Omnicell (NASDAQ:OMCL) will likely be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Omnicell to post earnings of $0.4175 per share and revenue of $304.43 million for the quarter. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%. Omnicell’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 EPS. On average, analysts expect Omnicell to post $1.41 EPS for the current fiscal year and $1.03 EPS for the next fiscal year.

Omnicell Price Performance

NASDAQ:OMCL opened at $36.97 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The stock’s 50-day simple moving average is $34.56 and its 200 day simple moving average is $39.43. The company has a market cap of $1.68 billion, a P/E ratio of 24.51, a P/E/G ratio of 0.95 and a beta of 0.98. Omnicell has a 52-week low of $29.09 and a 52-week high of $55.00.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on OMCL shares. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Wells Fargo & Company lowered their price target on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Finally, Zacks Research raised Omnicell from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Omnicell has an average rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.